Literature DB >> 32420094

Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis.

Bangrong Song1, Bo Yao2, Haiming Dang1, Ran Dong1.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common chromosomal abnormal heart disease. The pathophysiological mechanism of HCM is complex. Several studies have suggested that the level of Soluble ST2 (sST2) may be a biomarker of chronic systolic heart failure, however, the role of sST2 in HCM remains unclear. So we performed this study to analyze the role of Soluble ST2 (sST2), Galectin-3 (Gal-3) and its correlations with clinical prognosis of patients with hypertrophic cardiomyopathy (HCM) undergoing ventricular septal myectomy.
METHODS: HCM patients who underwent modified Morrow surgery in our hospital during June 2016-June 2018 were included. We divided the patients into different groups stratified by sST2 and Gal-3 level. Besides, we included volunteers without heart disease for medical examination as normal controls. Biochemical analyses were conducted to identify the biomarkers difference. The predictive value of sST2 and Gal-3 on all-cause mortality was evaluated with Cox regression analysis.
RESULTS: A total of 125 HCM patients were included in this present study. The sST2 and Gal-3 levels in HCM patients were significantly higher than that in control group (all P<0.001); there were significant differences in the incidence of all-cause mortality for HCM patients stratified by the sST2 and Gal-3 level; Cox univariate regression survival analysis showed that the hypertension (HR =1.19, 95% CI: 1.01-1.38), maximum wall thickness (HR =1.48, 95% CI: 1.04-1.98), Log sST2 (HR =1.02, 95% CI: 1.01-1.05), Log Gal-3 (HR =1.17, 95% CI: 1.09-1.32) were the predictors for all-cause mortality in patients with HCM, and Cox multivariate risk regression showed that maximum wall thickness was the independent predictors of all-cause mortality in patients with HCM (HR =1.63, 95% CI: 1.35-1.97).
CONCLUSIONS: Even through sST2 and Gal-3 were not associated with clinical prognosis of patients with HCM undergoing ventricular septal myectomy, it may be involved in the progress of HCM, more studies are warranted to identify the potential mechanism and reverence value. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Galectin-3 (Gal-3); Soluble ST2 (sST2); correlation; hypertrophic cardiomyopathy (HCM)

Year:  2020        PMID: 32420094      PMCID: PMC7225438          DOI: 10.21037/cdt.2020.01.04

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  38 in total

Review 1.  Soluble ST2 in heart failure.

Authors:  Benjamin Dieplinger; Thomas Mueller
Journal:  Clin Chim Acta       Date:  2014-09-28       Impact factor: 3.786

2.  Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure.

Authors:  Chao-Hung Wang; Mei-Ling Cheng; Min-Hui Liu; Li-Tang Kuo; Ming-Shi Shiao
Journal:  J Cardiol       Date:  2017-03-17       Impact factor: 3.159

Review 3.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 4.  Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Authors:  Gabrielle Norrish; Nicoletta Cantarutti; Eleni Pissaridou; Deborah A Ridout; Giuseppe Limongelli; Perry M Elliott; Juan Pablo Kaski
Journal:  Eur J Prev Cardiol       Date:  2017-05-09       Impact factor: 7.804

Review 5.  Review of recent advances in the management of hypertrophic cardiomyopathy.

Authors:  Y Cao; P-Y Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-11       Impact factor: 3.507

6.  Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction.

Authors:  Antonio Lax; Jesus Sanchez-Mas; Maria C Asensio-Lopez; Maria J Fernandez-Del Palacio; Luis Caballero; Iris P Garrido; Francisco J Pastor-Perez; James L Januzzi; Domingo A Pascual-Figal
Journal:  JACC Heart Fail       Date:  2014-11-12       Impact factor: 12.035

7.  Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy.

Authors:  Bruno Solano de Freitas Souza; Daniela Nascimento Silva; Rejane Hughes Carvalho; Gabriela Louise de Almeida Sampaio; Bruno Diaz Paredes; Luciana Aragão França; Carine Machado Azevedo; Juliana Fraga Vasconcelos; Cassio Santana Meira; Paulo Chenaud Neto; Simone Garcia Macambira; Kátia Nunes da Silva; Kyan James Allahdadi; Fabio Tavora; João David de Souza Neto; Ricardo Ribeiro Dos Santos; Milena Botelho Pereira Soares
Journal:  Am J Pathol       Date:  2017-03-17       Impact factor: 4.307

8.  Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction.

Authors:  M C Asensio-Lopez; A Lax; M J Fernandez Del Palacio; Y Sassi; R J Hajjar; J L Januzzi; A Bayes-Genis; D A Pascual-Figal
Journal:  J Mol Cell Cardiol       Date:  2019-04-15       Impact factor: 5.000

9.  Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model.

Authors:  Jaime Ibarrola; Ernesto Martínez-Martínez; J Rafael Sádaba; Vanessa Arrieta; Amaia García-Peña; Virginia Álvarez; Amaya Fernández-Celis; Alicia Gainza; Patrick Rossignol; Victoria Cachofeiro Ramos; Natalia López-Andrés
Journal:  Int J Mol Sci       Date:  2017-07-31       Impact factor: 5.923

10.  Galectin-3 alters the lateral mobility and clustering of β1-integrin receptors.

Authors:  Esther H Yang; Julia Rode; Md Amran Howlader; Marina Eckermann; Jobette T Santos; Daniel Hernandez Armada; Ruixiang Zheng; Chunxia Zou; Christopher W Cairo
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

View more
  1 in total

1.  Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis.

Authors:  Yujiao Shi; Guoju Dong; Jiangang Liu; Xiong Shuang; Chunqiu Liu; Chenguang Yang; Wang Qing; Wenbo Qiao
Journal:  Front Cardiovasc Med       Date:  2022-04-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.